Assess whether a CMC change is a comparability or a new product (d82bdd)

Situation

Scientific-advice briefing book arrived with an inspector asking for batch records you cannot produce this week for labeling negotiator. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on a CMC change is in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using scientific-advice briefing book after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled Clinical and Evidence Strategy process in an RWE group proposing a post-marketing study instead of a new RCT, given scientific-advice briefing book.
• An inspector asking for batch records you cannot produce this week is the event in scientific-advice briefing book that forces A CMC change is a comparability for labeling negotiator under Pharma & Life Sciences.
• Scientific-advice briefing book shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a Clinical and Evidence Strategy program failure.
• Scientific-advice briefing book cannot decide a CMC change is yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after an inspector asking for batch records you cannot produce this week). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.